https://www.facebook.com/share/v/14SNNtbVSs7
ZAS Corporation proudly participated in the Bangladesh International Cancer Congress (BICC) 2025, highlighting its oncology and biosimilar portfolio aimed at improving cancer care in Bangladesh.
During the congress, the ZAS oncology team engaged with leading medical professionals, sharing practical insights and discussing emerging advancements in cancer treatment. These interactions underscored ZAS’s ongoing commitment to making advanced therapies more accessible to patients in need. ZAS Corporation remains dedicated to supporting the medical community and contributing to better outcomes in oncology care across the country.